StreetAlpha.app
Home › Stocks › IOVA

Iovance Biotherapeutics, Inc. (IOVA)

Healthcare
$6.90
▼ −5.61%
LAST CLOSE · NOV 20

Iovance Biotherapeutics makes Amtagvi, a personalized cell therapy for advanced melanoma, and sells Proleukin, a related cancer drug. It last closed at $6.90 on Nov 20, down 5.61% on the day. The next earnings report for IOVA is expected around Tue, Feb 23, 2027. For the quarter ended Sep 2026, IOVA reported EPS of -$0.05 on revenue of $121.5M, with revenue up 80.1% from a year ago. Over its last 8 reports the stock moved an average of 26.3% the session after earnings.

AI Auto Pilots
Is IOVA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IOVA.

Key Stats

Last 12 months
Results
Revenue
$379.0M
+51.3% vs a year ago
Net income
−$220.5M
−58.2% margin
EPS (diluted)
−$0.49
Free cash flow
−$216.1M
−57.0% margin
Valuation
Market cap
$3.2B
462.7M shares
P/E
–
No P/E while losing money
Price to sales
8.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$57.9M
At Sep 30
Shareholder equity
$812.7M
Shares outstanding
462.7M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.2M$1.2MFY2023FY2024: $164.1M$164.1MFY2024FY2025: $263.5M$263.5MFY2025

From IOVA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 23
Estimated date · Time not announced
Reported EPS
-$0.05
Quarter ended Sep 2026
Year ago EPS
-$0.25
Same quarter last year
Revenue
$121.5M
+80.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.25Dec '24Mar 2025: -$0.36Mar '25Jun 2025: -$0.33Jun '25Sep 2025: -$0.25Sep '25Dec 2025: -$0.15Dec '25Mar 2026: -$0.19Mar '26Jun 2026: -$0.11Jun '26Sep 2026: -$0.05Sep '26Latest -$0.05
Revenue by quarter
Dec 2024: $73.7MDec '24Mar 2025: $49.3MMar '25Jun 2025: $60.0MJun '25Sep 2025: $67.5MSep '25Dec 2025: $86.8MDec '25Mar 2026: $71.4MMar '26Jun 2026: $99.3MJun '26Sep 2026: $121.5MSep '26Latest $121.5M
How IOVA moved after its last 8 reports
Average move the session after a report ±26.3%
Nov 5, 2026Time not announced−11.0%
Aug 6, 2026Time not announced+43.1%
May 7, 2026Time not announced−13.2%
Feb 24, 2026Time not announced+30.8%
Nov 6, 2025Time not announced+27.6%
Aug 7, 2025After the close−20.1%
May 8, 2025After the close−44.8%
Feb 27, 2025After the close−19.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IOVAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IOVA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IOVA

Technical Analysis

IOVA · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 30% below its 20 day and 63% below its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 29), oversold. The nearest support is the Pivot S1 at $6.65, and the nearest resistance the swing high (Aug 7) at $6.92.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityNormal, 11.3%/day
Key levels
$15.3752 week high+122.8%
$11.2250 day average+62.6%
$8.9520 day average+29.7%
$8.73100 day average+26.5%
$7.28Pivot R1+5.5%
$7.02Pivot+1.7%
$6.92Swing high (Aug 7)+0.3%
$6.90Last close
$6.65Pivot S1−3.6%
$6.23200 day average−9.7%
$3.96Swing low (Aug 3)−42.6%
$2.0852 week low−69.9%
Indicators
RSI (14)28.61Oversold below 30Oversold
MACD-1.30Below its signal lineBearish
Stochastic6.7Near the bottom of its rangeOversold
ADX (14)40.7Strong downtrend
Williams %R-94.6Oversold below −80, overbought above −20Oversold
CCI (20)-78.1Oversold below −100, overbought above 100Neutral
Rate of change−14.2%Change over 10 sessionsBearish
ATR (14)$0.78Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for IOVA

What happened before

See how IOVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IOVA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IOVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IOVAHow many large options trades hit IOVA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

IOVA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲189 buying vs 127 selling
  • ▼Held by funds -1.8 pts
  • ▲Funds holding +44
  • ▲Superinvestors: 3 added, 2 cut
  • ▲Put/call 2.45 to 1.10
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding336292+15.1%
In funds' top 1092+350.0%
Held by funds60.2%62.0%−1.8 pts
New / increased76 / 11341 / 130+10.5%
Reduced / sold out93 / 3464 / 36+27.0%
Put/call ratio1.102.45−55.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IOVA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IOVA Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 5, 2025Daniel Gordon KirbyChief Commercial OfficerBuy30,000$1.84$55K
May 23, 2025Raj K. PuriChief Regulatory OfficerBuy5,600$1.74$10K
May 14, 2025Frederick G VogtInterim CEO & General CounselBuy25,000$1.69$42K
Nov 12, 2024Ryan D MaynardDirectorSale50,000$10.06$503K
Every insider buy and sale for IOVA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IOVA insider trades →

From SEC Form 4 filings by IOVA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IOVA is in one of them and how their past IOVA trades turned out.

IOVA in the AI portfolios
Loading…

IOVA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IOVA in an article yet. Here's the latest on the wider market.

IOVA in the news

About Iovance Biotherapeutics

Iovance Biotherapeutics develops and sells cell therapies that use a patient's own immune cells to fight solid tumor cancers. Its main product, Amtagvi, is a single, personalized treatment for adults with advanced melanoma who have had prior treatment, and it is given at treatment centers. The company also sells Proleukin, an interleukin-2 product used in the Amtagvi treatment regimen and in other medical uses, through distributors and other clients. Based in San Carlos, California, Iovance serves cancer treatment centers and is developing therapies for other solid tumors.

Headquarters
San Carlos, CA
Founded
2007